These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 33222369)

  • 1. Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
    Liu Y; Sun LY; Zhu ZJ; Wei L; Qu W; Wang L; Yuan LL; Zeng ZG
    Int J Clin Pract; 2021 Apr; 75(4):e13843. PubMed ID: 33222369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report.
    Gunes AK; Demir I; Pehlivan M
    J Oncol Pharm Pract; 2021 Mar; 27(2):509-512. PubMed ID: 32762294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
    Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
    Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
    Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases.
    Patel H; Vogl DT; Aqui N; Shaked A; Olthoff K; Markmann J; Reddy R; Stadtmauer EA; Schuster S; Tsai DE
    Leuk Lymphoma; 2007 May; 48(5):885-91. PubMed ID: 17487731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
    Deng Z; Jiang L; Zhou T; Shen C; Chen Q; Xia Q
    Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):579-82. PubMed ID: 25224233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
    Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Transplant Lymphoproliferative Disorder (PTLD) Manifesting in the Oral Cavity of a 13-Year-Old Liver Transplant Recipient (LTx).
    Krasuska-Sławińska E; Minko-Chojnowska I; Pawłowska J; Dembowska-Bagińska B; Pronicki M; Olczak-Kowalczyk D
    Ann Transplant; 2015 Aug; 20():478-82. PubMed ID: 26285106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
    Filipec-Kanizaj T; Budimir J; Colić-Cvrlje V; Kardum-Skelin I; Sustercić D; Naumovski-Mihalić S; Mrzljak A; Kolonić SO; Sobocan N; Bradić T; Dolić ZM; Kocman B; Katicić M; Zidovec-Lepej S; Vince A
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():37-43. PubMed ID: 23126028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransplant lymphoproliferative disorder: morphological picture and diagnostic difficulties.
    Ziarkiewicz-Wróblewska B; Górnicka B; Suleiman W; Ołdakowska-Jedynak U; Wróblewski T; Bogdańska M; Ziółkowski J; Nowacka-Cieciura E; Foroncewicz B; Pileri SA; Durlik M; Paczek L; Krawczyk M; Wasiutyński A
    Transplant Proc; 2006; 38(1):168-72. PubMed ID: 16504694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
    Ranganathan S; Webber S; Ahuja S; Jaffe R
    Pediatr Dev Pathol; 2004; 7(4):348-60. PubMed ID: 14564542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
    Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
    Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
    Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
    Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
    Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
    Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.